Literature DB >> 18449410

Heparin and low-molecular-weight heparin.

Elaine Gray1, Barbara Mulloy, Trevor W Barrowcliffe.   

Abstract

Heparin is one of the oldest biological medicines, and has an established place in the prevention and treatment of venous thrombosis. Low-molecular-weight heparins (LMWH) have been developed by several manufacturers and have advantages in terms of pharmacokinetics and convenience of administration. They have been shown to be at least as effective and safe as unfractionated heparin and have replaced the latter in many indications. In this article the chemistry, mechanisms of action, measurement of anticoagulant activities, and clinical status of heparin and LMWH are reviewed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18449410     DOI: 10.1160/TH08-01-0032

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  54 in total

Review 1.  Limitations of conventional anticoagulant therapy and the promises of non-heparin based conformational activators of antithrombin.

Authors:  Qudsia Rashid; Poonam Singh; Mohammad Abid; Mohamad Aman Jairajpuri
Journal:  J Thromb Thrombolysis       Date:  2012-08       Impact factor: 2.300

2.  Preparation, separation, and conformational analysis of differentially sulfated heparin octasaccharide isomers using ion mobility mass spectrometry.

Authors:  Youjin Seo; Armann Andaya; Julie A Leary
Journal:  Anal Chem       Date:  2012-02-14       Impact factor: 6.986

3.  Focusing of low-molecular-mass heparins in polycationic polyacrylamide matrices.

Authors:  Gleb Zilberstein; Ilya Shlar; Leonid Korol; Emmanuil Baskin; Elisa Fasoli; Pier Giorgio Righetti; Giangiacomo Torri; Antonella Bisio; Shmuel Bukshpan
Journal:  Anal Chem       Date:  2009-08-15       Impact factor: 6.986

4.  Significance of heparanase in cancer and inflammation.

Authors:  Israel Vlodavsky; Phillip Beckhove; Immanuel Lerner; Claudio Pisano; Amichai Meirovitz; Neta Ilan; Michael Elkin
Journal:  Cancer Microenviron       Date:  2011-08-03

5.  Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin.

Authors:  Thangirala Sudha; Murat Yalcin; Hung-Yun Lin; Ahmed M Elmetwally; Tipu Nazeer; Thiruvengadam Arumugam; Patricia Phillips; Shaker A Mousa
Journal:  Cancer Lett       Date:  2014-04-24       Impact factor: 8.679

Review 6.  Understanding the time course of pharmacological effect: a PKPD approach.

Authors:  Daniel F B Wright; Helen R Winter; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

7.  The reversal of anticoagulation in clinical practice .

Authors:  Sally Thomas; Michael Makris
Journal:  Clin Med (Lond)       Date:  2018-08       Impact factor: 2.659

8.  Utilization rates of enoxaparin and heparin in deep venous thrombosis prophylaxis after education and electronic order change at a single institution: a quality improvement study.

Authors:  Linda Hoang; Shahidul Islam; Alexander Hindenburg
Journal:  J Thromb Thrombolysis       Date:  2018-11       Impact factor: 2.300

9.  Combinatorial therapeutic activation with heparin and AICAR stimulates additive effects on utrophin A expression in dystrophic muscles.

Authors:  Christine Péladeau; Aatika Ahmed; Adel Amirouche; Tara E Crawford Parks; Lucas M Bronicki; Vladimir Ljubicic; Jean-Marc Renaud; Bernard J Jasmin
Journal:  Hum Mol Genet       Date:  2015-10-22       Impact factor: 6.150

10.  Interaction of antithrombin with sulfated, low molecular weight lignins: opportunities for potent, selective modulation of antithrombin function.

Authors:  Brian L Henry; Justin Connell; Aiye Liang; Chandravel Krishnasamy; Umesh R Desai
Journal:  J Biol Chem       Date:  2009-06-04       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.